By considering stability as part of the cell line selection and cell banking paradigm, we can ensure that instability problems are not observed during clinical or commercial manufacturing.
Robin A. Heller-Harrison
Advertisement
Robin A. Heller-Harrison is the associate director and the corresponding author in the cell and molecular sciences group in the department of Drug Substance Development at Wyeth Biopharma
Articles by Robin A. Heller-Harrison
Advertisement
Latest Updated Articles
Managing Cell Line Instability and Its Impact During Cell Line DevelopmentPublished: June 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Trends in Formulation eBook October 2025
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
4
Analytics, Automation, and Quality Driving the Next Era of Drug Development
5
